Spark Therapeutics, Inc.
3737 Market Street
Philadelphia, PA 19104
Phone: (215) 220-9300Website: https://sparktx.com/Careers: sparktx.com/join-spark-team
- FDA Approves Luxturna (voretigene neparvovec-rzyl) Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss
19 December 2017
- Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational Luxturna (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inherited Retinal Disease
10 November 2017
- FDA Advisory Committee Unanimously Recommends Approval of Investigational Luxturna (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease
19 October 2017
Drugs Associated with Spark Therapeutics, Inc.
Spark Therapeutics, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Generic name: voretigene neparvovec
Drug class: miscellaneous ophthalmic agents
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|